Former NCCAM director now consulting
This article was originally published in The Tan Sheet
Executive Summary
Tampa-Fla. based Calgenex Corporation announces Sept. 14 Joseph Jacobs, MD, has joined the company as Consulting Medical Director. Jacobs, the first director of what it is now NCCAM, joins the firm to fight the effects of soft tissue calcification and inflammation, the firm says. "I think the folks at Calganex are onto something very exciting that may improve the lives of millions," Jacobs says. Calganex CEO and President Grant Carlson says, "As a consulting medical director he will help guide the clinical development of our products and communicate our message to both the medical community and the general public." Jacobs received his medical degree from Yale University and completed his residency at Dartmouth-Hitchcock Medical Center. Calganex was founded in February 2006...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.